Dr. Tinoco Suarez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-0463Fax+1 614-293-1704
Summary
- Dr. Gabriel Tinoco is a distinguished oncologist based in Columbus, OH, specializing in sarcomas. He earned his medical degree from the National University of Colombia in 2005, followed by an internal medicine residency at MedStar Health/Harbor Hospital (2008–2011). He then completed a fellowship in hematology and medical oncology at the University of Miami/Jackson Health System (2013–2016).
Dr. Tinoco's expertise encompasses sarcomas, personalized medicine, and clinical trials. He has received multiple research grants, authored numerous peer-reviewed publications, and plays a pivotal role in investigator-initiated trials. As a leading expert in clinical trial design and execution, he actively contributes to advancing cancer treatment through innovative research in sarcomas.
Education & Training
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2013 - 2016
MedStar Health/Harbor HospitalResidency, Internal Medicine, 2008 - 2011
National University of ColombiaClass of 2005
Certifications & Licensure
FL State Medical License 2011 - 2025
OH State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma.Shriya Deshmukh, Ciara Kelly, Gabriel Tinoco
Targeted Oncology. 2025-01-01 - Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC...Yvonne M Mowery, Karla V Ballman, Angela M Hong, Scott M Schuetze, Andrew J Wagner
Lancet. 2024-11-23 - 3 citationsA Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.Scott M Schuetze, Karla V Ballman, Rachel Heise, Kristen N Ganjoo, Elizabeth J Davis
Clinical Cancer Research. 2024-10-15
Journal Articles
- Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondr...Luyuan Li, Ana C Paz, Breelyn A Wilky, Britt Johnson, Karina Galoian, Andrew Rosenberg, Guozhi Hu, Gabriel Tinoco, Olaf Bodamer, Jonathan C Trent, PloS one, 9/14/2015
- The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.Tinoco G, Wilky BA, Paz-Mejia A, Rosenberg A, Trent JC, Am Soc Clin Oncol Educ Book., 5/2015
Professional Memberships
- Member
- Member
- Member
- Member
- Member
Other Languages
- Spanish, Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
